Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07428447

Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease

Sponsor: CND Life Sciences

View on ClinicalTrials.gov

Summary

Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually. Post-mortem studies reveal Lewy body pathology in some ET patients, suggesting a subset may have prodromal PD. Current diagnostic tools (DaTscan, SYNTap) are either insufficiently sensitive for early disease, too expensive, or too invasive for routine screening. The Syn-One Test offers a minimally invasive approach to detect phosphorylated α-synuclein (P-SYN) pathology in skin biopsies. Primary Objectives 1. Identify which ET patients have P-SYN pathology indicative of prodromal PD 2. Predict which patients are most likely to phenoconvert to PD

Key Details

Gender

All

Age Range

50 Years - 85 Years

Study Type

OBSERVATIONAL

Enrollment

300

Start Date

2026-02-18

Completion Date

2029-02

Last Updated

2026-08-25

Healthy Volunteers

No

Locations (4)

CND Clinical Research Center

Scottsdale, Arizona, United States

Neurology One

Orlando, Florida, United States

Norton Healthcare

Louisville, Kentucky, United States

Veracity Neurosciences LLC

Memphis, Tennessee, United States